Financials Consun Pharmaceutical Group Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-07 am EDT			5-day change	1st Jan Change
6.25 ^HKD	+3.82%		+6.84%	+31.03%

May. 07	Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program	MT
Mar. 29	Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	3,507	2,053	2,848	2,820	3,436	4,609	-	-
Enterprise Value (EV) ¹	2,677	2,053	2,848	820.3	3,436	1,737	1,270	4,609
P/E ratio	44.4 x	4.21 x	4.91 x	4.16 x	4.42 x	5.06 x	4.47 x	3.77 x
Yield	4.41%	9.15%	-	7.29%	-	6.07%	7.11%	-
Capitalization / Revenue	2.03 x	1.17 x	-	1.21 x	1.33 x	1.57 x	1.37 x	1.23 x
EV / Revenue	1.55 x	1.17 x	-	0.35 x	1.33 x	0.59 x	0.38 x	1.23 x
EV / EBITDA	4.76 x	3.03 x	-	1.1 x	4.13 x	1.54 x	1 x	3.14 x
EV / FCF	13,151,706 x	2,508,919 x	-	-	-	-	-	-
FCF Yield	0%	0%	-	-	-	-	-	-
Price to Book	1.76 x	0.95 x	-	0.94 x	-	1.02 x	0.87 x	-
Nbr of stocks (in thousands)	845,733	799,826	794,304	788,390	792,434	799,318	-	-
Reference price ²	4.147	2.567	3.585	3.577	4.335	5.767	5.767	5.767
Announcement Date	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,728	1,753	-	2,340	2,590	2,940	3,364	3,747
EBITDA ¹	562	676.9	-	744.8	832	1,125	1,271	1,469
EBIT ¹	488.8	605.1	-	668.4	753.9	1,042	1,208	1,381
Operating Margin	28.29%	34.52%	-	28.57%	29.11%	35.44%	35.91%	36.85%
Earnings before Tax (EBT) ¹	133.7	583.7	-	746.4	863.7	1,023	1,203	1,367
Net income ¹	79.82	498.8	590.2	682.9	784.5	928.4	1,044	1,240
Net margin	4.62%	28.46%	-	29.19%	30.29%	31.58%	31.04%	33.09%
EPS ²	0.0934	0.6100	0.7300	0.8600	0.9800	1.140	1.290	1.530
Free Cash Flow	203.6	818.4	-	-	-	-	-	-
FCF margin	11.78%	46.69%	-	-	-	-	-	-
FCF Conversion (EBITDA)	36.23%	120.89%	-	-	-	-	-	-
FCF Conversion (Net income)	255.04%	164.07%	-	-	-	-	-	-
Dividend per Share ²	0.1828	0.2349	-	0.2606	-	0.3500	0.4100	-
Announcement Date	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	830	-	-	2,000	-	2,872	3,339	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	204	818	-	-	-	-	-	-
ROE (net income / shareholders' equity)	3.85%	23.7%	-	23.7%	-	25%	23.5%	26%
ROA (Net income/ Total Assets)	2.1%	13%	-	14.8%	-	17%	16.3%	18%
Assets ¹	3,803	3,829	-	4,628	-	5,461	6,426	6,888
Book Value Per Share ²	2.350	2.700	-	3.800	-	5.670	6.650	-
Cash Flow per Share ²	-	-	-	-	-	1.120	1.290	-
Capex ¹	180	48.7	-	-	-	140	144	270
Capex / Sales	10.4%	2.78%	-	-	-	4.76%	4.28%	7.21%
Announcement Date	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.767 CNY

Average target price

7.272 CNY

Spread / Average Target

+26.09%

	1st Jan change	Capi.
CONSUN PHARMACEUTICAL GROUP LIMITED	+31.03%	616M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.32%	43.95B
OTSUKA HOLDINGS CO., LTD.	+21.31%	22.49B
SANDOZ GROUP AG	+11.68%	14.71B
CIPLA LIMITED	+11.31%	13.77B
ZYDUS LIFESCIENCES LIMITED	+42.32%	12.3B
ONO PHARMACEUTICAL CO., LTD.	-8.86%	7.03B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.33%	5.48B